Clinical Data Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma BioPharma DiveInitial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a donor-derived cell therapy.Clinical DataOncologyRead full story pharminent April 13, 2026 (Last updated: April 14, 2026) BioPharma Dive Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a donor-derived cell therapy. Clinical DataOncologyRead full story Post navigation Previous: FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial ResultsNext: Spyre drug for inflammatory bowel disease shows promise in early study Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
